AtriCure Inc. has reported strong Q2 results, with revenue up 17% and a raised revenue outlook, prompting multiple analysts to increase their stock price targets.

AtriCure Inc.’s stock performance is bolstered by the rapidly expanding ablation technology market, which is projected to reach $16.74 billion by 2034.